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Background. Lupus nephritis encompasses a wide range of
parenchymal injuries and severity. Better predictors of outcome
are needed for patients newly diagnosed with lupus nephritis,
so that an appropriate management strategy may be selected.
Methods. A single-center cohort of first renal biopsies for lu-
pus nephritis was chosen. Histologic sections of whole biopsy
cores were stained with picro-Sirius red, and light microscopic
images (×100) were digitally captured. Using a simple, freely
available software package, the cortex of each biopsy was eval-
uated for four different parameters: area occupied by nuclei,
intratubular space, fibrillary collagen, and collagenous matrix.
Clinical and laboratory data were collected retrospectively from
the time of biopsy and throughout follow-up.
Results. A high nuclear index at initial biopsy correlated with
clinical parameters of disease activity, at the time of biopsy. High
collagen matrix index predicted both relapse and progression to
end-stage renal disease (ESRD). The fibrillary collagen index
predicted progressive disease as assessed by doubling of serum
creatinine, and relapse. Increased tubular space also predicted
progressive disease as determined by doubling of creatinine and
renal death.
Conclusion. A simple automated system for objectively scor-
ing biopsies of lupus nephritis predicts renal survival and may
provide a useful adjunct to guide patient management.
Kidney involvement is common in systemic lupus ery-
thematosis (SLE), and both the disease itself and the im-
munosuppressive agents used in therapy add greatly to
morbidity and mortality. The course of lupus nephritis is
very variable, and it is important in selecting or modifying
a treatment strategy to identify those likely to progress to
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end-stage renal disease (ESRD), and who stand to ben-
efit most from the potentially toxic therapies currently
available.
Lupus nephritis can encompass almost any form of
glomerulonephritis, in addition to inflammatory intersti-
tial changes, microvascular and tubular injuries. A renal
biopsy is typically used to evaluate the particular types
and severity of parenchymal injury, and to estimate the
degree (stage) of presumptively irreversible parenchymal
atrophy and scarring. Serial renal biopsies may be help-
ful to evaluate response to treatment, transformation of
pattern and progression of the lupus nephritis.
Achieving a systematic, reproducible, and relevant cat-
egorization, grading and staging of lupus nephritides is
problematic. The World Health Organization (WHO)
has proposed morphologic classifications of untreated lu-
pus glomerular disease in 1975, 1982, and 1995. These
are valuable and widely used [1–6], but suffer from un-
availability of the original texts (out of print), some am-
biguity, lack of clarity in definitions (which have been
interpreted differently in various textbooks), and dif-
ferences between the various versions which confound
interpretation of clinical studies that do not specify the
particular version applied. More fundamental criticism
has also been made of the pathogenetic coherence of the
categories [7]. Moreover, individual patients show a vari-
ability of outcome that reduces the practical predictive
value of the categorization. Additional semiquantitative
activity and chronicity indices are widely used to augment
the prognostic information from WHO system [13, 14],
in particular with assessments of tubulointerstitial inflam-
mation, scarring, and atrophy. The value of these indices
remains controversial. Following the initial studies, the
activity index was not found to correlate with outcome
in a number of studies [2, 15–18]. The chronicity index
similarly had predictive value in some studies [17, 19–21]
but not others [2, 15, 18, 22, 23]. One major problem
highlighted has been lack of reproducibility, reflecting
the subjectivity of scoring [24, 25]. However, the positive
94
Hunter et al: Morphometry of lupus nephritis 95
correlation of scarring and tubular atrophy with poor
renal outcome in lupus nephritis and other glomeru-
lonephritides [14, 26, 27–29] suggests these parameters
might have greater utility if more objectively measured.
Recently, Hill et al [30] attempted to improve predic-
tive outcome using a more elaborate biopsy index. While
this has proven successful, each biopsy requires skilled
scoring of 22 separate criteria rendering such an index
impractical for regular use.
With the wide availability of digital imaging technol-
ogy, it is feasible to capture and evaluate images of the
renal biopsy. With this in mind, we aimed to develop
an inexpensive, simple, objective system for augment-
ing biopsy assessment of lupus nephritis using digital im-
ages of whole biopsy cores, employing freely available
computer software and standardized criteria. This sys-
tem does not require lengthy training or a skilled oper-
ator. Our results were correlated with disease outcome
and clinical disease markers.
METHODS
Patient selection
Pathology and nephrology clinical databases were
searched from 1986 to 2001 for all patients at a single
center who had a biopsy and a formal diagnosis of SLE
made before or subsequent to biopsy. A cohort of 48
patients with newly diagnosed lupus nephritis was identi-
fied. All had biopsy tissue available for analysis contain-
ing a minimum of five glomeruli. The original slides were
reviewed for diagnosis, WHO categorization, and activ-
ity and chronicity scores [13, 14], together with the orig-
inal immunofluorescence and electron microscopy. For
each case, an original spare section or newly cut paraf-
fin section (3 lm) was also stained with picro-Sirius red
and hematoxylin counterstain by standard histochemical
method [31].
Assessment of biopsies
The biopsy core with the most cortex was imaged (×100
magnification) in bright field with a digital capture system
(Openlab 3.0.0 software; Improvision, Lexington, MA,
USA), so that the whole core was photographed in five
to eight images. The light source and condenser were used
at fixed settings for all imaging. Each image was also dig-
itally captured using double polarized light, under which
fibrillary collagen gives a bright refractile signal. The light
source was set to maximum and images were captured us-
ing identical exposure times. Medulla and capsule were
excluded from further study. Analysis of the captured
color images was initially carried out using the Openlab
software (Improvision). Using several images as pilots,
extraneous nonrenal tissue was removed manually from
the image, then a digital “density slice” was determined
for tubular space area using the following lower and up-
per parameters, each ranging from 0 to 255: hue (50, 130),
saturation (0, 66) and intensity (130, 255). Nuclear area
was measured using hue (70, 120), saturation (0, 104), and
intensity (0, 90). From the birefringent images fibrillary
collagen area was measured using hue (90, 108), satura-
tion (0, 215) and intensity (160, 255). These values were
reproducible in all our biopsies, but the program available
to us required manually inputting the settings for each im-
age. In addition, biopsies were analyzed by free software
(Image J 1.30; National Institutes of Health, Bethesda,
MD, USA) (http://rsb.info.nih.gov). Images were con-
verted from red, green, and blue (RGB) color (as cap-
tured) to gray scale RGB stack, then differentiated into
three gray scale images representing red, green,and blue.
The gray scale is 0 (black) to 255 (white). For analysis, the
green-gray scale images were used. Again, pilot images
were used to determine the settings. Image space out-
side the biopsy core was removed manually, then lower
and upper gray scale thresholds were set for discrimina-
tion of, intratubular luminal space (135, 255), nuclei (0,
90 to 120), Sirius red-positive material (which included
nuclei) (0, 100 to 140), and refringent fibrillary collagen
(150, 255). By applying these thresholds to different biop-
sies, tubular space and fibrillary collagen were reliably
identified in all biopsies. The upper threshold required
to discriminate nuclei remained constant within all biop-
sies stained at one time but it was necessary to adjust
between batches stained at different times. Discrimina-
tion of Sirius red–positive material varied from biopsy to
biopsy. To improve further the reproducibility of nuclear
and collagenous matrix scoring, analysis of the histogram
plot (shown on Image J) of frequency against gray scale
values (0 to 255) gave a binomial distribution for all the
images. The gray scale value corresponding to the peak
of the first curve gave the upper threshold for measuring
nuclei plus collagenous matrix. The ascending slope of
the first peak of this histogram could be described by two
separate gradients for all images. The gray scale value
corresponding to the intersection of the separate gra-
dients gave the upper threshold for measuring nuclear
area. Both of these thresholds were reproducible between
biopsies and batches of staining. These discriminators
and the gray scale thresholds (above) were recorded as a
readily modifiable plug-in and activated in the computer
program, so that each image was subsequently analyzed
automatically (available from the authors). Both pro-
grams provide the percent area of the image which is pos-
itive for the specified parameter. Two software programs
(OpenLab and Image J) gave nearly identical readings.
Values from Image J rather than OpenLab were used
for the analysis since Image J could execute the analysis
automatically, whereas OpenLab required the user to in-
put the discriminators for each image.
Parameters were defined as follows. Tubular in-
dex was the percentage intratubular (luminal) space,
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including intraglomerular space, of the total cortical area.
The other indices were a percentage area of the cortical
tissue. Therefore, tubular space was subtracted from total
cortical area for each image to obtain area of cortical tis-
sue. Nuclear index was the percentage area of the cortical
tissue that comprised nuclei. Collagenous matrix index
was the percentage area of cortical tissue that contained
picro-Sirius red–stained material. Fibrillary collagen in-
dex was the percentage area of cortical tissue comprising
refringent collagen, as viewed with polarized light.
The original light micrograph is shown alongside the
digitized image for comparison (Fig. 1A). Percentage
tubular space was determined as the first parameter
(Fig. 1B). The remaining tissue was then assessed for per-
centage of tissue occupied by nuclei (Fig. 1C), or by Sirius
red material (Fig. 1D). The percentage of fibrillary colla-
gen [32] of the renal tissue was calculated from the image
captured under polarized light (Fig. 1E and F).
For comparison, all biopsies were assessed blindly for
WHO category [4] and the components of the activity
and chronicity indices scored [14].
Collection of clinical data
Electronic clinical databases and clinical notes were ac-
cessed for the collection of data at the time of the biopsy
(demographic data, creatinine, creatinine clearance, pro-
teinuria, plasma albumin, blood pressure, and drug
therapy) and during follow-up. Complete clinical and lab-
oratory data was retrieved for 41 of 48 (86%) patients, the
remainder had more than 80% of clinical and laboratory
data retrieved.
Patient management
Patients were managed at the physician’s discretion.
However, in general, all patients received antihyper-
tensive therapy if blood pressure exceeded 130/80 mm
Hg, and all with nephrotic syndrome received diuretic
therapy. Twenty-nine of 48 (60%) patients received
angiotensin-converting enzyme (ACE) inhibitors or an-
giotensin II receptor antagonists. Patients received im-
munosuppression according to the WHO category of
glomerulonephritis on renal biopsy. Class III disease
was treated with oral prednisolone with azathioprine
(1.5 mg/kg/24 hours) for 3 to 6 months or until remission,
followed by gradual reduction to maintenance doses.
Class IV disease was treated with oral cyclophosphamide
(1.5 mg/kg/24 hours) with oral prednisolone for 3 to
6 months, until remission followed by azathioprine and
prednisolone, gradually reduced to maintenance levels.
End points
The following end points were chosen and defined,
based on previous studies: complete remission (protein-
uria <0.3 g/24 hours, plasma albumin >34 g/L, and plasma
creatinine <100 lmol/L), partial remission (proteinuria
and plasma creatinine improved by >25%), moderate
relapse (within a 4-month period, an increase of serum
creatinine of >30 lmol/L or proteinuria >1 g/24 hours),
severe relapse (within a 4-month period an increase of
creatinine by >100 lmol/L), doubling of serum creati-
nine, ESRD, renal death, or nonrenal death.
Statistical analysis
Data were summarized by the median and quartiles,
and by percentages. Survival methods were used to test
the prognostic value of the automated biopsy indexes in
predicting the outcomes in the presence of censoring by
the Log-rank statistic. As an adjunct to analyzing the orig-
inal index values, patients were dichotomized into high
and low index by splitting the cohort at the index me-
dian and Kaplan-Meier plots were presented for illus-
tration. Cox proportional hazards analysis was used to
estimate hazard ratios (HRs) and 95% confidence inter-
vals (95% CIs) with the predictor indexes as continu-
ous variables and as dichotomous variables, after testing
the proportional hazards assumption. Rejection of the
proportional hazards assumption and significant inter-
action with follow-up time are noted where applicable.
Spearman’s rank correlation test was used to test for cor-
relation between the clinical disease activity parameters
at the time of biopsy and the indices. The SAS system, ver-
sion 8.2 (SAS Institute, Inc., Cary, NC, USA) was used.
RESULTS
Patient characteristics and follow-up
The 48 patients were predominantly young, adult, Cau-
casian women (Table 1). Nine of 39 (23%) had nephrotic
syndrome at presentation, and 39 of 48 (81%) had hyper-
tension, which was adequately controlled (sitting blood
pressure less than 130/80 mm Hg) in 28 of 48 (58%) at time
of biopsy. Renal function was significantly impaired at
presentation (creatinine >150 lmol/L) in 6 of 46 (15%).
The first renal biopsies showed the following distribu-
tion of WHO categories of lupus nephritis: nine patients
(19%) class II, 13 patients (27%) class III, 18 patients
(38%) class IV, and seven patients (15%) class V. The
median number of glomeruli on the biopsy, available for
analysis, was 16 (quartiles 7.5 and 21.25).
Patients were followed-up for a minimum of 2 months
and maximum of 258 months (median 63 months).
Despite therapy, 18 of 48 (37%) patients exhibited pro-
gressive renal disease (doubling of creatinine), and 10 of
48 (20.8%) reached ESRD. Seven of 48 patients died,
among which two of 48 (4.2%) deaths were ascribed to
renal failure.
Correlation of histologic variables with outcomes
Forty-eight first renal biopsies were categorized (WHO
classification) and quantified using the image analysis
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Fig. 1. Comparison of original light images with digitally analyzed micrographic images (×1000). Original bright field image stained with picro-
Sirius red (A) has been digitized to highlight tubular space in red, but to exclude no biopsy area in blue (B). Nuclei alone (C) and nuclei plus
Sirius red–positive material are highlighted (D). The original image was viewed by double polarized light (E) with the digitized image highlighting
fibrillary collagen for comparison (F).
software for nuclear index, tubular space, collagenous
matrix, and fibrillary collagen. The median and quartiles
for each of the indices is shown (Table 1). Using survival
analysis, the nuclear index did not significantly predict
time to doubling of creatinine, time to ESRD, or death
(Table 2). The nuclear index did, however, correlate with
markers of disease activity at the time of biopsy, includ-
ing creatinine clearance (r = −0.34, P < 0.05), 24-hour
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Table 1. Baseline and end point characteristics for patient group
Demographics
Total patients 48
Age at initial biopsy years 34 (23, 47)
Women% 81
Men% 19
Status at initial biopsy
Serum albumin g/L 35 (30, 41)
Creatinine lmol/L 95 (78, 115)
Glomerular filtration rate mL/min 79 (47, 103)
Proteinuria >1 g/24 hours% 54.1 (20 of 37)
Nephrotic syndrome% 19.5 (8 of 41)
Hypertension% 79.2 (38 of 48)
Active urine sediment% 65.7 (23 of 35)
Low C3% 42.5 (17 of 40)
Positive dsDNA% 61.8 (21 of 34)
Clinical outcomes
Complete remission% 54.3 (25 of 46)
Partial remission% 41.3 (19 of 46)
No remission% 21.7 (10 of 46)
Partial relapse% 52.8 (19 of 36)
Severe relapse% 30.6 (11 of 36)
Doubling of creatinine% 37.5 18 of 48)
End-stage renal disease% 20.8 10 of 48)
Death (renal)% 4.3 (2 of 47)
Death (nonrenal)% 0.6 (5 of 47)
Biopsy parameters
Nuclear index 18.0 (15.9, 21.7)
Fibrillary index 1.18 (0.63, 2.63)
Tubular index 11.7 (9.1, 15.2)
Matrix index 26.3 (22.7, 30.8)
Values are medians and quartiles or percentages.
proteinuria (r = 0.40, P < 0.05), and serum albumin (r =
−0.54, P < 0.01), but not levels of serum complement (C3
or C4) or dsDNA (Fig. 2). When the patients with high
and low nuclear index were dichotomized those who had
a high nuclear index at the time of biopsy were less likely
to relapse than those with low nuclear index (P = 0.02)
(Table 2).
Using survival analysis, fibrillary collagen was predic-
tive of doubling of creatinine (P = 0.01), and was also
predictive of severe relapse (P = 0.06). Figure 3 presents
the survival plot of the time to doubling of serum creati-
nine according to fibrillary collagen index split at the me-
dian. The proportional hazards assumption was rejected
as there was a significant interaction between the origi-
nal fibrillary index values and follow-up time (P = 0.01).
This plot reflects the interaction as the cumulative pro-
portions cross at around 60 months, thus the impact of a
high fibrillary collagen content was delayed for around
5 years. A high fibrillary index was protective until 60
months with a HR of 0.91, but after 60 months the HR
for a high fibrillary index in predicting double creatinine
was 5.2.
Using survival analysis, those with greater than the me-
dian amount of collagen matrix (Sirius red–positive ma-
terial) were predisposed to progression to ESRD (P =
0.06) and were more likely to relapse (P = 0.06) (Table 2)
(Fig. 4). The HR for progression to ESRD was 6.4, de-
noting a sixfold increase in risk of ESRD in patients with
higher collagen matrix area. The rather wide CI around
the HR (0.72 and 57.1) reflects the small population avail-
able for study and the delay in collagen deposition having
an impact on progressive disease in the face of immuno-
suppressive therapies. Furthermore, a high collagen ma-
trix index appeared to predict those patients who died for
causes other than renal failure (P = 0.01)
Using survival analysis, the tubular index, a marker
of damaged tubules, significantly predicted doubling of
creatinine (P = 0.05) and renal death (P = 0.03) (Table 2,
Fig. 5). The HR for doubling of creatinine was 2.5 (Fig. 5),
and for ESRD was 4.1 in those patients with a higher
tubular index. The wide CIs (0.77 and 7.9) reflect both the
small population and a delay in impact of tubular index
on progressive disease. Given the intense therapy many
lupus patients receive it is not surprising that a marker of
tubular atrophy, the tubular index results in progressive
renal attrition only after a number of years.
The established scoring methods were compared with
our new objective indices. In addition to using the
computer-generated indices as reported we also scored
blindly each biopsy for the WHO disease categories and
the activity and chronicity index. The semiquantitative
atrophy and fibrosis scores of the chronicity index were
higher in patients with shorter time to ESRD (HR = 1.9,
P = 0.09; HR = 2.0, P = 0.06, respectively). When
the semiquantitative fibrosis scores (from the activ-
ity/chronicity indices) were compared with our new,
automated collagenous matrix index and the fibrillary
collagen index respectively no significant correlation was
found (r = 0.07, P = 0.2; r = 0.08, P = 0.2, respectively).
The tubular atrophy score (from the activity/chronicity
indices) was compared with our new tubular index and
a weak positive correlation was observed (r = 0.26,
P = 0.07) although this was not significant. Our new nu-
clear index was compared with the semiquantitative en-
docapillary proliferation score and the tubulointerstitial
mononuclear score (from the activity/chronicity index).
No correlations were observed (r = 0.01, P = 0.8; r =
0.03, P = 0.6, respectively). These results highlight the
difficulty an observer faces making an accurate estimate
of the amount of scarring or atrophy in a biopsy compared
with an objective automated method as used in our new
indices. Using survival analysis to determine whether the
disease end points were predicted by the WHO glomeru-
lar disease categories, we found that no category pre-
dicted any clinical outcome (data not shown). When
the new indices described here were compared with the
WHO disease categories no correlations were observed
between high index values and disease categories (data
not shown).
DISCUSSION
The present observations show the practicability and
utility of simple computer-aided morphometry to sup-
plement renal biopsy evaluation in lupus nephritis. The
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Table 2. Hazard ratios (HR) for automated biopsy indices in predicting clinical endpoints
Matrix Fibrillary Nuclear Tubular
End point HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value
Double creatinine
(A) 1.05 (0.96, 1.15) 0.31 1.52 (1.07, 2.16) 0.01 1.09 (0.95, 1.26) 0.22 1.09 (0.99, 1.19) 0.05
(B) 1.61 (0.55, 4.67) 0.38 2.89 (0.93, 9.03) 0.05 1.47 (0.52, 4.22) 0.47 2.48 (0.77, 7.94) 0.11
End-stage renal disease
(A) 1.09 (0.93, 1.28) 0.28 0.88 (0.50, 1.53) 0.65 1.07 (0.87, 1.31) 0.50 1.03 (0.89, 1.20) 0.67
(B) 6.41 (0.72, 57.1) 0.06 1.2 (0.22, 6.65) 0.85 2.00 (0.35, 11.3) 0.43 4.10 (0.47, 35.4) 0.16
Moderate relapse
(A) 1.03 (0.92, 1.15) 0.60 1.11 (0.77, 1.60) 0.58 0.85 (0.71, 1.03) 0.09 1.03 (0.94, 1.15) 0.49
(B) 2.73 (0.90, 8.27) 0.06 1.35 (0.455, 1.04) 0.59 0.23 (0.06, 0.88) 0.02 1.04 (0.36, 2.98) 0.94
Severe relapse
(A) 1.05 (0.92, 1.21) 0.45 1.50 (0.97, 2.33) 0.06 0.88 (0.69, 1.13) 0.28 1.07 (0.95, 1.20) 0.29
(B) 2.62 (0.64, 10.6) 0.16 1.88 (0.49, 7.19) 0.35 0.32 (0.06, 1.60) 0.14 1.58 (0.39, 6.49) 0.52
Renal death 0.81 (0.63, 1.05) 0.08 0.25 (0.02, 3.63) 0.25 1.28 (0.91, 1.78) 0.11 1.23 (0.99, 1.53) 0.03
Other death 1.27 (1.04, 1.56) 0.01 1.25 (0.78, 2.02) 0.34 0.93 ((0.73, 1.18) 0.53 1.06 (0.91, 1.23) 0.48
Values are the hazard ratio, 95% confidence interval, and P value. (A) is relative risk of end point for an increase of one point in the index; (B) is relative risk of end
point for an index value over the index median.
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Fig. 2. Correlation of nuclear index with clin-
ical parameters at the time of biopsy. Corre-
lation curves demonstrate positive correlation
with proteinuria (r = 0.40, P < 0.05) (A). Neg-
ative correlation of nuclear index with creati-
nine clearance (r = −0.34, P < 0.05) (B). Neg-
ative correlation plasma albumin (r = −0.55,
P < 0.01) (C).
prime advantage of such an approach is the robustness
and ease of quantification for variables that are not read-
ily reproducibly quantifiable even by the skilled pathol-
ogist, unaided. With our approach, a typical biopsy takes
about 10 minutes to fully image, capture, and evaluate.
The evaluation is easily performed by technical staff, and
the resulting images stored for future review if necessary.
We have avoided considerations of more complex selec-
tion of areas of cortex to measure, such as exclusion of
glomeruli or vessels, since a prime goal for this approach
was simplicity of execution. Similar semiautomated mor-
phometric evaluations of renal biopsy immunostaining
have been reported to be useful and reproducible [33].
All the indices measured involve a high contrast signal
(stain vs. no stain) and therefore can be anticipated to be
reproducible in other hands. Sirius red is also a robust his-
tochemical stain that is resistant to acid and light fading.
All histologic sections were cut with the microtome set
to 3 lm thickness, but since the system simply measures
the area of color (stain) it is unlikely that modest differ-
ences in section thickness will affect the results. Hence,
measurement of tubular space and fibrillary collagen was
impervious to all variables intrinsic to biopsies (age, fix-
ation, thickness, batch staining), although nuclear stain-
ing did show minor batch variability. This was noticeable
during analysis by Image J only. However, the variability
was overcome by using an upper gray scale threshold that
was relative to the colors in the biopsy image rather than
a fixed value. It was important to maintain fixed light,
condenser, and camera exposure settings, although a
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Fig. 3. Survival plot of the proportion without doubling of serum crea-
tinine as a function of time from biopsy according to fibrillary collagen
index split at the median. There was a significant interaction between
the fibrillary index and follow-up time (P = 0.01). After 60 months, the
hazard ratio for a high fibrillary index in predicting progressive disease
was 5.2.
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Fig. 4. Survival plot of the proportion without reaching end-stage renal
disease (ESRD) as a function of time from biopsy according to collagen
matrix index. Those patients with higher than the median collagen ma-
trix index (26.4%) at presentation exhibited more rapid progression to
ESRD compared with a lower index with a sixfold greater risk [hazards
ratio (HR) 6.4; 95% confidence interval (95% CI) 0.7, 57; P = 0.06].
variation of up to 10% in luminosity was tolerated well by
the system. Were such techniques to be widely employed
within different laboratories, interlaboratory variabilities
could be usefully quantified and monitored within exist-
ing interlaboratory quality control systems for techniques
potentially subject to similar or greater variability, such
as light chain and other immunohistochemistry methods
[e.g., the United Kingdom National External Quality As-
sessment Scheme for Immunohistochemistry (NEQUAS
for ICC)].
The patient demographics and spread of clinical char-
acteristics at presentation of our cohort are comparable
with previous work in this area. The distribution of WHO
classes and rates of progressive renal disease are also
similar to the available studies [2, 6, 8, 9, 20, 30, 34].
Twelve of 48 biopsies had fewer than seven glomeruli
available for histologic categorization. WHO categoriza-
tion is focused on the glomerulus, and in practice, renal
pathologists require at least seven glomeruli to reach an
accurate diagnosis. The lack of predictive or prognostic
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Fig. 5. Survival plot of the proportion without doubling serum crea-
tinine as a function of time according to the tubular index. The pro-
portional hazards assumption was rejected as there was a significant
interaction between the original tubular index values and follow up
time (P = 0.05). Those patients with higher than median tubular index
(11.7%) exhibited more rapid progression to doubling of creatinine with
2.5 times the risk compared with those patients lower than the median.
This difference was not significant, however [hazards ratio (HR) 2.5;
95% confidence interval (95% CI) 0.8, 7.9; P = 0.1).
value in the WHO classification of our cohort is unsurpris-
ing. The WHO category is useful for guiding immunosup-
pression, but does not precisely identify which patients
will develop progressive renal disease. In common with
other categorization systems, the WHO system has utility
when applied to large groups, but is much less predictive
of outcome for a particular individual, due to wide vari-
ation within these groups [7].
The particular parameters we selected have precedents
for relevance in the evaluation of lupus nephritis. Austin
et al [13, 14] first demonstrated that evaluations of the
biopsies of patients with lupus nephritis might have pre-
dictive value. The factors they identified included nuclear
infiltrate, scarring, and tubular atrophy. We believe that
a high nuclear index in our series reflects an influx of
immune and inflammatory cells such as occurs with active
disease, and to some extent also the reactive enlargement
of epithelial nuclei in injured tubules, and proliferation of
endogenous glomerular cells. It is therefore cogent that
the index has significant correlations with other markers
of disease activity. Although Hill et al [30] have correlated
specifically macrophage influx in lupus biopsies with poor
outcome, and others have also found inflammatory infil-
trates to be associated with parameters of progressive
disease [27, 30, 35, 36], our nuclear index did not corrob-
orate those findings. It is possible that since the nuclear
index looks at all nuclei, it is much less sensitive than im-
munohistochemical methods for detecting inflammatory
cells such as monocytes. Unexpectedly, a low nuclear in-
dex predicted those patients who would relapse (Table 2).
Since the index measures all nuclei, patients with severely
diseased tubules might be expected to have smaller nu-
clei due to development of mesenchymal characteristics
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by injured epithelial cells, and fewer overall nuclei as a
result of tubule obsolescence. Thus, although a high index
might reflect influxing immune cells, a low index will not
necessarily indicate a healthy kidney.
The morphometric assessment of refringent, fibrillary
collagen under polarized light microscopy is well de-
scribed [32]. Fibrillary collagen is more difficult to break
down than other forms of collagen and is likely to re-
flect chronic deposition of durable collagen relevant to
long-term parenchymal scarring. It is striking that the
doubling of creatinine predicted by increased fibrillary
collagen was only achieved late after biopsy (Fig. 3), in-
dicating correlation with a slower process of progressive
functional attrition. This is in keeping with an evalua-
tion of a quantity representing an accumulation of in-
juries to the kidney and one which is unlikely to have a
short-term dramatic impact on function. In keeping with
the predictive value of fibrillary collagen, the collagen
matrix index, reflecting the area of Sirius red stain on
the biopsy was also predictive of poor outcome for the
kidney. Sirius red stains collagens, but binds many more
collagen components, and is likely to reflect that matrix
which can be degraded or synthesized more rapidly. Not
surprisingly, the fibrillary and matrix indices correlated
weakly with one another (r = 0.4, P = 0.03), but some pa-
tients had large amounts of Sirius red staining with little
fibrillary collagen. The survival analysis pointed to pre-
dictive value of the collagen matrix index only when the
patient groups were dichotomized. This would suggest
that there is not a linear relationship between collagen
matrix deposition and poor outcome; rather that only in
those individuals with large amounts of collagen matrix
will the outcome be poor. The predictive value of inter-
stitial scarring on a renal biopsy for poor outcome is com-
mon to a variety of chronic renal diseases [29, 37, 38] as
well as lupus nephritis [13, 14]. Importantly, Howie et al
[29] recently reported a more subjective, semiautomated
system for measuring scarring in periodic acid-Schiff
(PAS)-stained renal biopsies [29]. They also found that
such scarring at initial diagnostic biopsy correlated with
development of ESRD. Thus our completely automated
system supports further the importance of interstitial fi-
brosis in renal deterioration.
Our intratubular space index is at first sight a rather
unlikely quantity to have correlations with outcome.
However, injured tubules supported in a scarred, con-
tracting interstitium, have a reduced thickness of perime-
ter epithelium and correspondingly enlarged central lu-
minal space. Injured epithelia undergo epithelial to mes-
enchymal dedifferentiation taking on a flattened, spread-
out morphology. In addition, tubular cells, shed from the
basement membrane, contribute to tubular obstruction,
enhancing further the tubular space [39]. The expanded
Bowman’s space around shrunken, diseased glomeruli
also contributes somewhat to this measure. Hence, the
index can be taken as an easily quantified measure
of parenchymal atrophy. Tubular atrophy has been as-
sociated with progressive renal deterioration in other
diseases [40]. In lupus nephritis it forms a part of the
chronicity index and has been shown independently to
be a predictor of progression [14, 41]. The present ob-
servation that intratubular space predicted renal disease
progression (doubling of creatinine, renal death) is there-
fore congruent with past findings.
The main weakness of the study is the limited num-
ber of biopsies for investigation. However, the predictive
value of the parameters measured is supported by nonau-
tomated data from other sources [14, 27, 29, 39, 40]. It
would be advantageous to test this method in another,
perhaps larger cohort of lupus biopsies, and in a cohort
of patients with another progressive glomerular disease
such as IgA nephropathy.
CONCLUSION
We have shown that readily measurable indices of col-
lagen matrix, fibrillary collagen, and intratubular space
all correlate with poor outcome criteria in patients with
lupus nephritis undergoing standard treatment regimens.
Thus we have identified markers of progression at the
time of starting treatment. In addition, our nuclear index
correlates with markers of disease activity at the time
of the biopsy. These new indices, which are inexpensive
and reproducible to determine using different analysis
software, appear to be useful predictors of progressive
disease. As an adjunct to the WHO categorization of
glomerular disease in lupus it may be beneficial to con-
sider applying these measures prospectively in the eval-
uation of lupus nephritis.
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